TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9877488
Drug: Budesonide 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide 1.0 mg by inhalation from a pMDI with a Nebuhaler (with charcoal)
Study: 9877488
Drug: Budesonide 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide 1.0 mg by inhalation from a pMDI with a Nebuhaler (without charcoal)
Study: 9877488
Drug: Budesonide 0.5
Normalized name: budesonide 0.5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide 0.5 mg given intravenously
Study: 9877488
Drug: Erroneous administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Erroneous administration (canister shaken only before the first actuation)
Study: 7891985
Drug: 0.5% apraclonidine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% apraclonidine, topically twice daily for 1 week
Study: 17531897
Drug: Uterotonic medications
Normalized name: UTEROTONICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Uterotonic medications
Study: 16301850
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (PAC group): PPI (bid), amoxicillin (1,000 mg, bid), clarithromycin (500 mg, bid)
Study: 16301850
Drug: Quadruple therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadruple therapy (PBMT group): PPI (bid), bismuth subcitrate (300 mg, qid), metronidazole (500 mg, tid), tetracycline (500 mg, qid)
Study: 11932285
Drug: Glucose ingestion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose ingestion (50 g)
Study: 11932285
Drug: Glucose ingestion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose ingestion (50 g) during mental stress
Study: 9654311
Drug: i.v./oral therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v./oral therapy with ciprofloxacin plus metronidazole
Study: 9654311
Drug: i.v. therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. therapy with ciprofloxacin plus metronidazole
Study: 7628206
Drug: Medroxyprogesterone acetate
Normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medroxyprogesterone acetate 25 mg plus oestradiol cypionate 5 mg (Cyclofem)
Study: 7628206
Drug: Norethisterone enanthate
Normalized name: norethindrone enanthate
DrugBank: Norethindrone enanthate (DB14678)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norethisterone enanthate 50 mg plus oestradiol valerate 5 mg (Mesigyna)
Study: 2692825
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg of ketanserin sublingually
Study: 2692825
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of ketanserin intravenously
Study: 2692825
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg of nifedipine sublingually
Study: 401691
Drug: Molsydomine 2
Normalized name: molsidomine
DrugBank: Molsidomine (DB09282)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Molsydomine 2 mg
Study: 19025527
Drug: 50 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg/kg i.v. magnesium sulphate in 100 ml of 0.9% normal saline
Study: 19025527
Drug: 50 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg/kg i.v. magnesium sulphate
Study: 17157115
Drug: Paracetamol/tramadol (PIT)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol/tramadol (PIT) 325 mg/37.5 mg
Study: 17157115
Drug: Tramadol (T)
DrugBank: Tramadol (DB00193)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tramadol (T) 50 mg
Study: 12684211
Drug: Duodenal fat
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duodenal fat infusion (triglyceride emulsion, 2.8 kcal/min)
Study: 12684211
Drug: Duodenal fat
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duodenal fat infusion with lipase inhibition (120 mg tetrahydrolipstatin)
Study: 11014323
Drug: Telmisartan 1-160
Normalized name: Telmisartan
DrugBank: Telmisartan (DB00966)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Telmisartan 1-160 mg oral single dose
Study: 11014323
Drug: Telmisartan 10-160
Normalized name: telmisartan 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan 10-160 mg intravenous single dose
Study: 11014323
Drug: Telmisartan 320
Normalized name: Telmisartan
DrugBank: Telmisartan (DB00966)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Telmisartan 320 mg oral once daily for 7 days
Study: 11014323
Drug: Telmisartan 20
Normalized name: telmisartan 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan 20 and 120 mg oral once daily for 7 days
Study: 11014323
Drug: Telmisartan 10,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan 10, 20, 40, 80, 120, and 160 mg oral once daily for 7 days
Study: 11014323
Drug: Telmisartan 40,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan 40, 80, or 120 mg oral once daily for 28 days
Study: 3590805
Drug: High-dose prednisolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose prednisolone (2 g of prednisolone-hemisuccinate every 6 hours for 48 hours)
Study: 29340809
Drug: Intraincisional ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraincisional ropivacaine 0.2% (3 ml)
Study: 29340809
Drug: Intrapertioneal ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrapertioneal ropivacaine 0.2% (20 ml)
Study: 18689718
Drug: Nisin (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nisin (6 microg/mL) applied to the nipple and mammary areola for 2 weeks
Study: 18689718
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (similar preparation devoid of nisin)
Study: 16708816
Drug: Harnal (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Harnal (0.2 mg/d)
Study: 16708816
Drug: Proscar (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proscar (5 mg/d)
Study: 12778355
Drug: Intensive chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive chemotherapy according to AML-BFM 93 protocol
Study: 2252527
Drug: prednisone (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: prednisone (15 mg/day)
Study: 393464
Drug: indomethacin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: indomethacin (100 mg/day)
Study: 28504569
Drug: Blended essential
Normalized name: Io-Blend
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blended essential oil (1:1:1 ratio of L. angustifolia, Salvia sclarea, and Origanum majorana)
Study: 25801289
Drug: THC administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: THC administration
Study: 19705105
Drug: Ketotifen (sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketotifen (sedating antihistamine)
Study: 19705105
Drug: Epinastine (nonsedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epinastine (nonsedating antihistamine)
Study: 11712038
Drug: Topical aspirin/dichloromethane
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical aspirin/dichloromethane solution
Study: 25955224
Drug: Transdermal testosterone
Normalized name: testosterone Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal testosterone (20 μg/kg/d)
Study: 25955224
Drug: Transdermal estradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal estradiol (200 μg/d)
Study: 25955224
Drug: Combined estrogens
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined estrogens and oral contraceptive pills (30 μg of ethinyl estradiol plus 150 μg of desogestrel) and 4 mg/d of estradiol valerate
Study: 23104720
Drug: Adjuvant trastuzumab-based
Normalized name: Rna-based adjuvant cv8102
DrugBank: CV-8102 (DB19184)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant trastuzumab-based chemotherapy (ATBC)
Study: 23104720
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (ATBC-)
Study: 10205316
Drug: Folate supplementation
Normalized name: folate
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folate supplementation (5 mg/day)
Study: 1425625
Drug: ondansetron 1
Normalized name: ondansetron 16 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ondansetron 1 mg
Study: 6372428
Drug: Supplement group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplement group (high-protein beverage)
Study: 6372428
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (routine vitamin and mineral tablets)
Study: 20102879
Drug: Full-dose tenecteplase
Normalized name: Tenecteplase
DrugBank: Tenecteplase (DB00031)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Full-dose tenecteplase before PCI (f-PCI)
Study: 16333795
Drug: Continuous anticoagulation
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous anticoagulation therapy (INR 2.0 - 3.0) in patients with AF and LA thrombi
Study: 12668861
Drug: Glycoprotein IIb/IIIa
Normalized name: GLYCOPROTEIN IIB/IIIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycoprotein IIb/IIIa inhibitors (specifically abciximab)
Study: 12668861
Drug: Thienopyridines and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thienopyridines and glycoprotein (GP) IIb/IIIa inhibitors
Study: 7649753
Drug: Generic discharge
Approvals — FDA: no, EMA: no, PMDA: no
Description: Generic discharge screens indicating IV fluids or drugs
Study: 29382477
Drug: 1 day
Normalized name: ZonaCort 11 Day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 day preparation with PEG 3350 (4 g/kg/day) + bisacodyl
Study: 29382477
Drug: 2 days
Normalized name: Chapstick 12 Days of Christmas KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 days preparation with PEG 3350 (2 g/kg/day) + bisacodyl
Study: 23090524
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg mifepristone and 800 micrograms buccal misoprostol
Study: 18594529
Drug: VAPEC-B+G-CSF
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: VAPEC-B+G-CSF
Study: 12043955
Drug: Solution-based intranasal
Normalized name: NALOXONE RESCUE KIT INTRANASAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution-based intranasal triamcinolone acetonide formulation (Tri-Nasal) at doses of 100, 200, and 400 microg over 7 days
Study: 12043955
Drug: Aqueous suspension-based
Normalized name: penicillin G procaine Injectable Suspension [Pen-Aqueous]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aqueous suspension-based triamcinolone acetonide formulation (Nasacort AQ) at doses of 110, 220, and 440 microg
Study: 10421591
Drug: Oral folic
Normalized name: folic acid Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral folic acid (5 mg PO) for 4 weeks
Study: 10421591
Drug: Oral folic
Normalized name: folic acid Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral folic acid (5 mg PO)
Study: 27279544
Drug: Everolimus (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus (10 mg once a day)
Study: 31182181
Drug: Low glycaemic
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low glycaemic index, low insulin index (LGI-LII) meal
Study: 27832514
Drug: On-demand treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: On-demand treatment with BAY 81-8973
Study: 15043519
Drug: Oral branched
Normalized name: Machilus thunbergii branch extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral branched chain amino acids
Study: 11764826
Drug: MD15 Oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: MD15 Oral Irrigator plus manual brushing
Study: 9493701
Drug: Barnidipine 20
Normalized name: barnidipine
DrugBank: Barnidipine (DB09227)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Barnidipine 20 mg
Study: 9493701
Drug: Barnidipine 30
Normalized name: barnidipine
DrugBank: Barnidipine (DB09227)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Barnidipine 30 mg
Study: 3324615
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg diclofenac sodium
Study: 3947505
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg diclofenac sodium
Study: 30392496
Drug: PsP 750mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: PsP 750mg/day in 3 divided doses for 90 days
Study: 25335686
Drug: Milk enriched
Normalized name: MILK
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milk enriched with sterols (2.24 g per day)
Study: 22417253
Drug: Oral laquinimod
Normalized name: laquinimod
DrugBank: Laquinimod (DB06685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral laquinimod 0.6 mg once daily
Study: 12604533
Drug: Amoxicillin 25
Normalized name: amoxicillin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin 25 mg/kg/dose b.i.d.
Study: 12604533
Drug: Amoxicillin 15
Normalized name: amoxicillin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin 15 mg/kg/dose t.i.d.
Study: 10390311
Drug: Electrical stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electrical stimulation (ES) of wrist extensors (3 times 30 minutes daily for 8 weeks)
Study: 16269638
Drug: Standard rehabilitation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard rehabilitation treatment
Study: 2005315
Drug: Exposure to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exposure to IgE sensitizing agents
Study: 6650801
Drug: Midazolam 0.2
Normalized name: midazolam 0.2 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 0.2 mg kg‐1 i.v.
Study: 6650801
Drug: Thiopentone 5
Normalized name: Thiopentone
DrugBank: Thiopental (DB00599)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Thiopentone 5 mg kg‐1 i.v.
Study: 31250427
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care (medication reconciliation)
Study: 30941435
Drug: Beak trimming
Normalized name: phentermine hydrochloride Oral Capsule [Oby-Trim]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beak trimming twice (7 and 70 days old)
Study: 22055112
Drug: FOLF-CB (cetuximab
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLF-CB (cetuximab 400 mg/m2 day 1 cycle 1; subsequent doses 250 mg/m2 weekly, along with bevacizumab, leucovorin, and 5-FU)
Study: 22055112
Drug: mFOLFOX6-B (bevacizumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: mFOLFOX6-B (bevacizumab 5 mg/kg, oxaliplatin 85 mg/m2, leucovorin 400 mg/m2, and 5-FU 400 mg/m2 then 1200 mg/m2/day for 48 hours)
Study: 19182972
Drug: Er:YAG laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Er:YAG laser (30 Hz, 60 mJ for 10 sec, without water/air spray)
Study: 16055645
Drug: Training in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Training in Oriental medicine
Study: 16055645
Drug: Length of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Length of training in Oriental medicine
Study: 2660550
Drug: Sucralfate suspension
Normalized name: Sucralfate
DrugBank: Sucralfate (DB00364)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sucralfate suspension 1 g/10 ml four times per day
Study: 2660550
Drug: Cigarette smoking
Normalized name: Cigarette smoking tobacco
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cigarette smoking (regardless of treatment group)
Study: 20724681
Drug: Active water
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active water treatment units
Study: 20724681
Drug: Sham water
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham water treatment units
Study: 15561950
Drug: GAD antibody
Normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
Approvals — FDA: no, EMA: no, PMDA: no
Description: GAD antibody positive patients
Study: 15561950
Drug: GAD antibody
Normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
Approvals — FDA: no, EMA: no, PMDA: no
Description: GAD antibody negative patients
Study: 2917399
Drug: Opti-Free chemical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opti-Free chemical disinfectant under normal daily use (Group A)
Study: 2917399
Drug: Normal daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal daily use regimen (Group B)
Study: 21747241
Drug: Valsartan 160
Normalized name: valsartan 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan 160 mg monotherapy
Study: 30273819
Drug: Leucine-enriched amino
Normalized name: Leucine
DrugBank: Leucine (DB00149)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Leucine-enriched amino acid supplement
Study: 30273819
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no leucine-enriched amino acid supplement)
Study: 28545580
Drug: Cognitive behavior
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavior therapy (CBT) after 5 therapy-preparing sessions
Study: 26325427
Drug: Intra-oral autologous
Normalized name: Autologous cultured fibroblasts
DrugBank: Azficel-T (DB11051)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-oral autologous bone graft
Study: 26325427
Drug: Implant stability
Normalized name: respiratory syncytial virus pre-fusion F protein, A, recombinant, stabilized / respiratory syncytial virus pre-fusion F protein, B, recombinant, stabilized Injection [Abrysvo]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implant stability quotient (ISQ)
Study: 19624628
Drug: Supraclavicular block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supraclavicular block with 2% lidocaine 25‐30 ml and adrenaline 5 microg.ml(‐1)
Study: 19624628
Drug: Infraclavicular block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infraclavicular block with 2% lidocaine 25‐30 ml and adrenaline 5 microg.ml(‐1)
Study: 11706909
Drug: Acetaminophen (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen (600 mg) with codeine (60 mg) and caffeine (15 mg) (Tylenol No. 3)
Study: 18334689
Drug: Monthly personal
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly personal contact
Study: 17142406
Drug: Hip core
Normalized name: HIP
DrugBank: Heme iron polypeptide (DB11067)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hip core decompression followed by physical therapy
Study: 14563339
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with abciximab (0.25mg/kg bolus and 0.125 microg/kg/min for 12h) and half‐dose reteplase (two boluses of 5U 30 min apart) with reduced‐dose heparin (60 Ukg(‐1) bolus, maximum 5000 U, followed by an infusion of 7 Ukg(‐1)h(‐1))
Study: 14563339
Drug: Reteplase alone
Normalized name: reteplase
DrugBank: Reteplase (DB00015)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reteplase alone (10 U bolus twice, 30 min apart) with standard‐dose heparin (5000 U bolus followed by an infusion of 1000 Uh(‐1) for patients > or =80 kg and 800 Uh(‐1) for those <80 kg)
Study: 11056590
Drug: HIV‐1 Immunogen
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIV‐1 Immunogen administered intramuscularly every 12 weeks
Study: 4029017
Drug: Temocillin 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temocillin 0.5 g intravenous
Study: 4029017
Drug: Temocillin 1
Normalized name: temocillin
DrugBank: Temocillin (DB12343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temocillin 1 g intravenous
Study: 4029017
Drug: Temocillin 2
Normalized name: temocillin
DrugBank: Temocillin (DB12343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temocillin 2 g intravenous
Study: 4029017
Drug: Temocillin 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temocillin 0.5 g intramuscular
Study: 4029017
Drug: Dose-reduction factors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-reduction factors for temocillin
Study: 29415606
Drug: Ibuprofen medicated
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen medicated plaster
Study: 17378911
Drug: Ghrelin concentration
Normalized name: Ghrelin
DrugBank: Lenomorelin (DB11895)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ghrelin concentration greater than 3,200 pg/mL (fourth quartile)
Study: 9788404
Drug: Combined chemoradiotherapy
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined chemoradiotherapy (5-fluorouracil, mitomycin C, and radiation therapy)
Study: 2650015
Drug: Acyclovir in
Normalized name: acyclovir Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acyclovir in propylenglycol (40% cream)
Study: 31617562
Drug: Clinical geriatric
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical geriatric assessments and collaborative medication reviews by geriatrician and family physician (FP)
Study: 28118537
Drug: AMG 811
Normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMG 811 (180 mg)
Study: 17455207
Drug: Weekend 5-ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekend 5-ASA enema (1 g twice a week) plus oral 5-ASA (3 g/day)
Study: 17455207
Drug: Oral 5-ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral 5-ASA only (3 g/day)
Study: 14522627
Drug: Benzoyl peroxide
Normalized name: Benzoyl Peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Benzoyl peroxide 4% gel (BID)
Study: 14522627
Drug: Adapalene 0.1%
Normalized name: ADAPALENE 0.1% GEL,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adapalene 0.1% gel (QD)
Study: 10968648
Drug: Acupuncture in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture in combination with tooth extraction
Study: 10968648
Drug: Acupuncture used
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture used in combination with local anesthesia
Study: 9202556
Drug: SR alfuzosin
Approvals — FDA: no, EMA: no, PMDA: no
Description: SR alfuzosin 5 mg twice daily
Study: 1283570
Drug: Verapamil SR
Normalized name: Dom-Verapamil SR
DrugBank: Verapamil (DB00661)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Verapamil SR 240 mg/day
Study: 28415881
Drug: Step by
Normalized name: By Ache
Approvals — FDA: no, EMA: no, PMDA: no
Description: Step by Step treatment protocol (intervention)
Study: 27367159
Drug: Spironolactone 20
Normalized name: spironolactone 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone 20 mg once daily (up to 40 mg once daily for 4 weeks if required)
Study: 25069531
Drug: 10‐mg metoclopramide
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10‐mg metoclopramide thrice daily for 15 days
Study: 25069531
Drug: 10‐mg placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10‐mg placebo thrice daily for 15 days
Study: 19272808
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (splint, heat, and exercise)
Study: 17289855
Drug: Bilateral eccentric
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral eccentric overload strength training using the Bromsman device twice a week